Positive Interactions With EMA Provide Route to Conditional Marketing Authorization of Lead Candidate Nefecon
- Tuesday, October 1, 2019, 1:40
- Finance
- Add a comment
STOCKHOLM, Oct. 1, 2019 /PRNewswire/ — Calliditas Therapeutics AB (publ) (“Calliditas”) today announced that the European Medicines Agency (EMA) has provided positive guidance related to a conditional marketing authorization (CMA) of the company’s lead compound Nefecon, currently in…
About the Author
adminasapcorp has written 38951 stories on this site.